Warren Buffett's Berkshire Hathaway scored a $60 million gain on Biogen shares after they surged to a record high on Monday. Federal regulators approved the biotech company's Aduhelm drug — the ...

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug ...

Biogen expects to do better this year on a key metric of financial health after a strong performance this summer from its newer products, including Leqembi, the closely watched drug for Alzheimer ...

Viehbacher also led Biogen’s largest-ever acquisition last year, buying Reata Pharmaceuticals Inc. for $7.3 billion to gain its approved therapy for Friedreich’s ataxia, a rare ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Click here for access. * Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180. * An analyst from Morgan Stanley has ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...